1. Home
  2. BJDX vs PFSA Comparison

BJDX vs PFSA Comparison

Compare BJDX & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluejay Diagnostics Inc.

BJDX

Bluejay Diagnostics Inc.

HOLD

Current Price

$4.89

Market Cap

1.8M

Sector

Health Care

ML Signal

HOLD

PFSA

Profusa Inc.

HOLD

Current Price

$0.22

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BJDX
PFSA
Founded
2015
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
1.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BJDX
PFSA
Price
$4.89
$0.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.2M
220.0K
Earning Date
05-12-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
86.65
N/A
EPS
N/A
N/A
Revenue
$249,040.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$0.05
52 Week High
$7.00
$4.22

Technical Indicators

Market Signals
Indicator
BJDX
PFSA
Relative Strength Index (RSI) 70.46 28.94
Support Level $1.46 $0.12
Resistance Level $7.00 $0.41
Average True Range (ATR) 0.80 0.03
MACD 0.17 0.00
Stochastic Oscillator 58.95 0.00

Price Performance

Historical Comparison
BJDX
PFSA

About BJDX Bluejay Diagnostics Inc.

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Share on Social Networks: